Close

UCB presents new data about the real-world experience of FINTEPLA® (fenfluramine) and rare epilepsy syndromes at 2023 American Epilepsy Society (AES) Annual Meeting

Go back to UCB presents new data about the real-world experience of FINTEPLA® (fenfluramine) and rare epilepsy syndromes at 2023 American Epilepsy Society (AES) Annual Meeting
UCB Unsponsored ADR (AMEX: UCBJY) Delayed: 64.54 +0.86 (1.35%)
Previous Close $63.68    52 Week High $46.25 
Open $64.52    52 Week Low $32.74 
Day High $64.86    P/E N/A 
Day Low $64.31    EPS $0.00 
Volume 3,535